Literature DB >> 35941396

Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam.

Anton Straub1, Andreas Vollmer2, Thiên-Trí Lâm3, Roman C Brands2, Maximilian Stapf4, Oliver Scherf-Clavel4, Max Bittrich5, Andreas Fuchs2, Alexander C Kübler2, Stefan Hartmann2.   

Abstract

OBJECTIVES: Mechanisms of wound healing are often impaired in patients with osteonecrosis of the jaw (ONJ). According to the guidelines for the treatment of this disease, early surgical intervention is indicated. However, surgery often faces complications such as wound healing disorders. The application of platelet-rich fibrin (PRF) after necrosectomy between bone and mucosa may constitute a promising approach to improve surgical results. An aspect that was not investigated until now is that PRF acts as a "bio-carrier" for antibiotics previously applied intravenously.
MATERIALS AND METHODS: We investigated the antimicrobial properties of PRF in 24 patients presenting ONJ undergoing systemic antibiosis with ampicillin/sulbactam. We measured the concentration of ampicillin/sulbactam in plasma and PRF and performed agar diffusion tests. Ampicillin/sulbactam was applied intravenously to the patient 10 minutes for blood sampling for PRF. No further incorporation of patients' blood or PRF product with antibiotic drugs was obtained. Four healthy patients served as controls.
RESULTS: Our results revealed that PRF is highly enriched with ampicillin/sulbactam that is released to the environment. The antibiotic concentration in PRF was comparable to the plasma concentration of ampicillin/sulbactam. The inhibition zone (IZ) of PRF was comparable to the standard ampicillin/sulbactam discs used in sensitivity testing.
CONCLUSIONS: The results of our study demonstrated that PRF is a reliable bio-carrier for systemic applied antibiotics and exhibits a large antimicrobial effect. CLINICAL RELEVANCE: We describe a clinically useful feature of PRF as a bio-carrier for antibiotics. Especially when applied to poorly perfused tissues and bone such as in ONJ, the local release of antibiotics can reduce wound healing disorders like infections.
© 2022. The Author(s).

Entities:  

Keywords:  ARONJ; Agar diffusion test; Antiresorptive drug-related osteonecrosis of the jaw; Oral microbiome; Osteonecrosis of the jaw; Osteoradionecrosis

Year:  2022        PMID: 35941396     DOI: 10.1007/s00784-022-04663-y

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.606


  34 in total

1.  Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw.

Authors:  S Bocanegra-Pérez; M Vicente-Barrero; M Knezevic; J M Castellano-Navarro; E Rodríguez-Bocanegra; J Rodríguez-Millares; D Pérez-Plasencia; A Ramos-Macías
Journal:  Int J Oral Maxillofac Surg       Date:  2012-05-28       Impact factor: 2.789

2.  The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws.

Authors:  Thomas Mücke; Steffen Koerdt; Maximilian Jung; David A Mitchell; Klaus-Dietrich Wolff; Marco Rainer Kesting; Denys John Loeffelbein
Journal:  J Craniomaxillofac Surg       Date:  2016-01-08       Impact factor: 2.078

3.  Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges.

Authors:  Morten Schiodt; Sven Otto; Stefano Fedele; Alberto Bedogni; Ourania Nicolatou-Galitis; Roman Guggenberger; Bente Brokstad Herlofson; Oliver Ristow; Thomas Kofod
Journal:  Oral Dis       Date:  2019-08-19       Impact factor: 3.511

Review 4.  Use of platelet-rich fibrin in regenerative dentistry: a systematic review.

Authors:  Richard J Miron; Giovanni Zucchelli; Michael A Pikos; Maurice Salama; Samuel Lee; Vincent Guillemette; Masako Fujioka-Kobayashi; Mark Bishara; Yufeng Zhang; Hom-Lay Wang; Fatiha Chandad; Cleopatra Nacopoulos; Alain Simonpieri; Alexandre Amir Aalam; Pietro Felice; Gilberto Sammartino; Shahram Ghanaati; Maria A Hernandez; Joseph Choukroun
Journal:  Clin Oral Investig       Date:  2017-05-27       Impact factor: 3.573

5.  Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases.

Authors:  Marco Mozzati; Giorgia Gallesio; Valentina Arata; Renato Pol; Matteo Scoletta
Journal:  Oral Oncol       Date:  2012-01-20       Impact factor: 5.337

Review 6.  Platelet-Rich Fibrin and Soft Tissue Wound Healing: A Systematic Review.

Authors:  Richard J Miron; Masako Fujioka-Kobayashi; Mark Bishara; Yufeng Zhang; Maria Hernandez; Joseph Choukroun
Journal:  Tissue Eng Part B Rev       Date:  2016-10-10       Impact factor: 6.389

7.  Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics.

Authors:  Lieselotte De Bruyn; Ruxandra Coropciuc; Wim Coucke; Constantinus Politis
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-12-11

8.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

9.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

Review 10.  Denosumab: mechanism of action and clinical outcomes.

Authors:  D A Hanley; J D Adachi; A Bell; V Brown
Journal:  Int J Clin Pract       Date:  2012-09-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.